Year: 2024

UAB Partnerystės projektai keturi Notes partial redemption and interest payment

Written by Customer Service on October 28, 2024. Posted in Public Companies.

UAB Partnerystės projektai keturi (“the Issuer“) is pleased to announce the Mandatory partial redemption of Notes and the semi-annual interest payment. The principal repayment constitutes 50% of the aggregate principal amount of the Notes (section 7.4 under Terms & Conditions). The Notes are being redeemed from each Noteholder on a pro rata basis. As reported on 8 April 2024, the Project has been successfully constructed and handed over to the Ministry of National Defence of the Republic of Lithuania. Since then, compensation payments under the Public Private Partnership have been received and are partly being used for funding this redemption. We remind the Noteholders that on 28 April 2025, there is a Voluntary redemption at the option of the Issuer (section 7.3 under the Terms & Conditions) for the remaining part...

BioSenic provides third quarter 2024 Business Update

Written by Customer Service on October 28, 2024. Posted in Earnings Releases And Operating Results.

BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024. Key highlightsIn July 2024, BioSenic signed of global licensing, supply and commercialization agreements with Phebra Pty Ltd. related to the adaptation of the License Agreement and the MDA signed earlier in May 2021, when Phebra became a minority shareholder in Medsenic SAS. In July 2024, BioSenic filed of the continuation patent application US 18/763,376 with...

Philips delivers strong margin improvement; flat comparable sales due to further deteriorated demand in China; growth in rest of world

Written by Customer Service on October 28, 2024. Posted in Earnings Releases And Operating Results.

October 28, 2024 Third-quarter highlightsGroup sales amounted to EUR 4.4 billion, with flat comparable sales growth Income from operations was EUR 337 million Adjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of sales Operating cashflow of EUR 192 million, with a free cashflow of EUR 22 million Comparable order intake decreased by 2%, due to decline in China Outlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current rangeRoy Jakobs, CEO of Royal Philips:“In the quarter, demand from hospitals and consumers in China further deteriorated, while we continue to see solid growth in other regions. We have adjusted...

Mowi ASA (OSE:MOWI): Presentation of Q3 2024 results 6 November 2024 at 08:00 (CET)

Written by Customer Service on October 28, 2024. Posted in Public Companies.

Mowi ASA hereby invites you to the presentation of the results for the third quarter 2024 at Hotel Continental, Stortingsgaten 24/26, 0117 Oslo, Norway. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/ A recording of the webcast will be made available on our website immediately afterwards. Please note that the quarterly report and presentation will be published at 06:30 (CET).This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Written by Customer Service on October 28, 2024. Posted in Public Companies.

Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Written by Customer Service on October 27, 2024. Posted in Public Companies.

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, LongeveronOral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2% heart transplantation rate ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatment Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation ELPIS...

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Written by Customer Service on October 27, 2024. Posted in Public Companies.

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori...

ECARX Powers Global Launch of the smart #5 Premium Mid-Size SUV

Written by Customer Service on October 27, 2024. Posted in Public Companies.

SHANGHAI, Oct. 27, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, in partnership with AMD, the high performance and adaptive computing leader, today celebrated the official launch of smart #5, smart’s first premium mid-size SUV which integrates ECARX’s Makalu® computing platform powered by AMD Ryzen™ Embedded V2000 Series processors. Dr. Lisa Su, Chairman and CEO of AMD, congratulated smart via video at the launch event. The smart #5 made its global debut in Australia in August, showcasing its forward-thinking design embodying Mercedes-Benz’s “Sensual Purity” design philosophy. Leveraging the powerful AMD Ryzen™ Embedded V2000 Series processors and ECARX’s Makalu® computing platform and Cloudpeak® software platform, smart delivers a unique...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Written by Customer Service on October 27, 2024. Posted in Public Companies.

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 development IgA Nephropathy (IgAN) is a leading cause of chronic kidney disease with up to 40% of IgAN patients progressing to end stage kidney disease about 20 years after diagnosisCAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy (IgAN). The results showed substantial...

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

Written by Customer Service on October 26, 2024. Posted in Public Companies.

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic rapid decline1Fabhalta also showed a favorable safety profile with no new safety signals1Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments2-5Novartis continues to advance multi-asset renal portfolio; C3G regulatory submissions completed in EU, China and Japan, and expected in US by year-endBasel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals